Skip to main content

Table 4 Analgesic use according to the experience of bone complications

From: Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

OutcomeAt-risk periodaPatient populationEU5b
N = 813
France
N = 146
Germany
N = 175
Italy
N = 173
Spain
N = 141
UK
N = 173
Patients who received analgesics by at-risk period, n (%)c
 Any analgesic useOverallAll patients461 (57)102 (70)110 (63)84 (49)94 (67)66 (38)
With BCs162 (76)36 (90)34 (71)35 (71)25 (86)27 (63)
Without BCs299 (50)66 (62)76 (60)49 (40)69 (62)39 (30)
Period 2All patients457 (56)104 (71)110 (63)84 (49)93 (66)60 (35)
With BCs160 (75)34 (85)35 (73)33 (67)26 (90)28 (65)
Without BCs296 (49)70 (66)75 (59)51 (41)67 (60)32 (25)
Period 3All patients234 (29)43 (30)66 (38)46 (27)10 (7)32 (19)
With BCs89 (42)15 (38)21 (44)22 (45)21 (72)13 (30)
Without BCs145 (24)28 (26)45 (35)24 (19)31 (28)19 (15)
Patients who received analgesics by stepc and at-risk period, n (%)d
 Step 1OverallAll patients255 (31)38 (26)70 (40)56 (32)51 (36)47 (27)
 Step 2192 (24)46 (32)50 (29)30 (17)36 (26)25 (15)
 Step 3162 (20)51 (35)37 (21)21 (12)34 (24)10 (6)
 Step 1With BCs73 (34)11 (28)18 (38)21 (43)9 (31)14 (33)
 Step 272 (34)15 (38)11 (23)16 (33)12 (41)16 (37)
 Step 372 (34)21 (53)18 (38)10 (20)12 (41)7 (16)
 Step 1Without BCs182 (30)27 (26)52 (41)35 (28)42 (38)33 (25)
 Step 2120 (20)31 (29)39 (31)14 (11)24 (21)9 (7)
 Step 389 (15)30 (28)19 (15)11 (9)22 (20)3 (2)
 Step 1Period 2All patients216 (27)30 (21)63 (36)50 (29)36 (26)41 (24)
 Step 2165 (20)39 (27)49 (28)23 (13)31 (22)19 (11)
 Step 3144 (18)46 (32)33 (19)18 (10)32 (23)8 (5)
 Step 1With BCs65 (30)8 (20)16 (33)18 (37)8 (28)16 (37)
 Step 262 (29)14 (35)12 (25)12 (24)9 (31)13 (30)
 Step 359 (28)16 (40)16 (33)7 (14)11 (38)6 (14)
 Step 1Without BCs150 (25)22 (21)47 (37)32 (26)28 (25)25 (19)
 Step 2102 (17)25 (24)37 (29)11 (9)22 (20)6 (5)
 Step 386 (14)30 (28)17 (13)11 (9)21 (19)2 (2)
 Step 1Period 3All patients130 (16)17 (12)39 (22)30 (17)52 (37)21 (12)
 Step 282 (10)14 (10)27 (15)15 (9)30 (21)13 (8)
 Step 356 (7)15 (10)17 (10)7 (4)13 (9)5 (3)
 Step 1With BCs40 (19)5 (13)9 (19)15 (31)7 (24)6 (14)
 Step 233 (15)3 (8)8 (17)8 (16)8 (28)8 (19)
 Step 333 (16)3 (8)8 (17)4 (8)7 (24)4 (9)
 Step 1Without BCs90 (15)12 (11)30 (24)15 (12)23 (21)15 (12)
 Step 249 (8)11 (10)19 (15)7 (6)5 (5)5 (4)
 Step 323 (4)6 (6)9 (7)3 (2)3 (3)1 (1)
  1. BCs bone complications, EU5 five European countries (France, Germany, Italy, Spain and the UK), UK United Kingdom
  2. aOverall: from multiple myeloma diagnosis to disease progression following first-line treatment; period 2: during active first-line therapy; period 3: after treatment discontinuation. Note that analgesic use was not recorded for period 1 (before initiation of induction therapy)
  3. bAggregated EU5 data have been weighted based on the multiple myeloma incidence in each country so base sizes for individual countries may not equal the EU5 total
  4. cStep on the World Health Organization analgesic ladder
  5. dExpressed as a percentage of the total number of patients, patients with BCs or patients without BCs, as indicated (patient numbers by country – EU5 with BCs: 214; EU5 without BCs: 599; France with BCs: 40; France without BCs: 106; Germany with BCs: 48; Germany without BCs: 127; Italy with BCs: 49; Italy without BCs: 124; Spain with BCs: 29; Spain without BCs: 112; UK with BCs: 43; UK without BCs: 130)